Clinical and economic impact of herpes zoster vaccination in elderly in Italy

References

• Piano Nazionale Prevenzione Vaccinale (PNPV). (PNPV) 2012–2014. Gazzetta Ufficiale n.47 (12 Marzo 2012). Ministero della Salute. Disponibile a: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1721_allegato.pdf.
   Google Scholar
• Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013; 10(4):e1001420; PMID:23585738; http://dx.doi.org/10.1371/journal.pmed.1001420
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352(22):2271-84; PMID:15930418; http://dx.doi.org/10.1056/NEJMoa051016
   PubMed Web of Science ®Google Scholar
• Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 Years. J Infect Dis 2016; pii:jiw047.
   Google Scholar
• Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145:317-25; PMID:16954357; http://dx.doi.org/10.7326/0003-4819-145-5-200609050-00004
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Virapongse A, Smith KJ. Costeffectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280-8; PMID:17443464; http://dx.doi.org/10.1086/514342
   PubMed Web of Science ®Google Scholar
• Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med 2015; 163:489-97; PMID:26344036; http://dx.doi.org/10.7326/M15-0093
   PubMed Web of Science ®Google Scholar
• Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25:8326-37; PMID:17980938; http://dx.doi.org/10.1016/j.vaccine.2007.09.066
   PubMed Web of Science ®Google Scholar
• Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008; 4:238-45; PMID:18382137; http://dx.doi.org/10.4161/hv.4.3.5686
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27:1454-67; PMID:19135492; http://dx.doi.org/10.1016/j.vaccine.2008.12.024
   PubMed Web of Science ®Google Scholar
• van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res 2010; 10:237; PMID:20707884; http://dx.doi.org/10.1186/1472-6963-10-237
   PubMed Web of Science ®Google Scholar
• Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc 2010; 8:7; PMID:20433704; http://dx.doi.org/10.1186/1478-7547-8-7
   PubMedGoogle Scholar
• Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin 2011; 7:749-56; PMID:21606685; http://dx.doi.org/10.4161/hv.7.7.15573
   PubMed Web of Science ®Google Scholar
• Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2013; 13:393-406; PMID:23537397; http://dx.doi.org/10.1586/erp.13.19
   PubMed Web of Science ®Google Scholar
• Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and postherpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother 2015; 11:884-96; http://dx.doi.org/10.1080/21645515.2015.1011561
   PubMed Web of Science ®Google Scholar
• Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine 2012; 30:675-84; PMID:22120193; http://dx.doi.org/10.1016/j.vaccine.2011.10.036
   PubMed Web of Science ®Google Scholar
• Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res 2013; 13:359; PMID:24070414; http://dx.doi.org/10.1186/1472-6963-13-359
   PubMed Web of Science ®Google Scholar
• de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine 2013; 31:1276-83; PMID:23306360; http://dx.doi.org/10.1016/j.vaccine.2012.12.067
   PubMed Web of Science ®Google Scholar
• Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A. Cost-effectiveness analysis of herpes zoster vaccination in Italian elderly persons. Int J Technol Assess Health Care 2016: 32(4):233-40; PMID:27064102
   PubMed Web of Science ®Google Scholar
• Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics 2013; 31:125-36; PMID:23335045; http://dx.doi.org/10.1007/s40273-012-0020-7
   PubMed Web of Science ®Google Scholar
• Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine 2014; 32:1645-53; PMID:24534737; http://dx.doi.org/10.1016/j.vaccine.2014.01.058
   PubMed Web of Science ®Google Scholar
• de Boer PT, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination against herpes zoster. Hum Vaccin Immunother 2014; 10:2048-61; PMID:25424815; http://dx.doi.org/10.4161/hv.28670
   PubMed Web of Science ®Google Scholar
• Demo.istat. Demografia in cifre. Istituto Nazionale di Statistica. Popolazione residente al 1 Gennaio 2015 per età, sesso e stato civile. Available at: http://demo.istat.it.
   Google Scholar
• Demo.istat. Demografia in cifre. Istituto Nazionale di Statistica. Speranza di vita alla nascita e a 65 anni, per sesso e regione – Anni 2008–2011. Available at: http://demo.istat.it.
   Google Scholar
• Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis 2011; 11:173; PMID:21679419; http://dx.doi.org/10.1186/1471-2334-11-173
   PubMed Web of Science ®Google Scholar
• Accordo Collettivo Nazionale per la disciplina dei rapporti con i medici di medicina generale ai sensi dell'art. 8 del D.lgs. N. 502 del 1992 e successive modificazioni ed integrazioni quadriennio normativo 2006–2009, biennio economico 2006–2007. Available at: http://www.sisac.info/aree/www.sisac.info/resources/MEDICINA_GENERALE/ACN%2029%20luglio%202009/ACN_Medicina_Generale_consolidato%281%29.pdf.
   Google Scholar
• Atto d'acquisto N. 9/SPE del 17.02.2015. Fornitura annuale, dalla data del presente atto, del “VACCINO ZOSTAVAX (p.a.Vaccino vivo dell'herpes zoster)”, per l'ULSS 7 pieve di soligo (TV).
   Google Scholar
• Istituto Nazionale di Statistica. Rivaluta: Rivalutazioni e documentazione su prezzi, costi e retribuzioni contrattuali. Disponibile a: http://rivaluta.istat.it.
   Google Scholar
• Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo R, Volpi A. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010; 10:230; PMID:20682044; http://dx.doi.org/10.1186/1471-2334-10-230
   PubMed Web of Science ®Google Scholar